Boston Scientific to acquire Penumbra in $14.5 billion deal
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
Experts caution that realizing AI’s potential requires careful management and risk mitigation
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
Subscribe To Our Newsletter & Stay Updated